冠心消渴安胶囊对糖尿病合并冠心病大鼠模型胰岛素抵抗和炎性指标的影响

发布时间：2018-09-18 13:47

【摘要】：糖尿病合并冠心病是在糖尿病基础上由各种致病因素共同导致的心血管体统病变一种伴发症或并发症。在我国近年来随着糖尿病的发病率越来越高,而糖尿病合并冠心病的发病率也逐步增加,严重影响了人民群众的健康。中医药在对该病治疗积累了很多经验,我们应该挖掘中医药这个千年积累的宝库,从而找出新路。以减轻社会、患者家庭的经济负担,减少服药种类,减轻服药痛苦。冠心消渴安胶囊是杜廷海教授研制的既能治疗糖尿病又能保护心血管的中成药。希望通过本次动物实验研究来印证冠心消渴安胶囊的药效及药用机理。目的:建立糖尿病合并性冠心病大鼠模型。观察造模后大鼠模型心电图及大鼠模型的冠脉和心肌组织的病理切片。通过试验观察冠心消渴安胶囊对糖尿病冠心病大鼠模型空腹血糖(Fasting plasma glucose FPG)、空腹胰岛素(Fasting insulin FINS)、胰岛素敏感指数(Insulin sensitivity index ISI)、胰岛素抵抗指数(Insulin resistance index IRI)、C反应蛋白(C-reactive protein CRP)、白介素-6(Interleukin IL-6)水平的影响,验证冠心消渴安胶囊防治糖尿病合性冠心病疗效,并初步探明药用机理,为临床用药提供可靠的实验依据。方法:将大鼠用高脂饲料喂养后,用链脲佐菌素对大鼠进行腹腔注射,建立糖尿病大鼠模型。在建立糖尿病大鼠模型后,给大鼠腹腔注射垂体后叶素注射液制备出糖尿病合并冠心病大鼠模型。通过对大鼠的心电图、冠脉及心肌组织的病理切片的观察来判定大鼠模型建立的结果。将制备好的模型分成空白对照组(A组)、模型对照组(B组)、二甲双胍组对照组(C组)、冠心消渴安胶囊对照组(D组)。分组后开始灌胃治疗,空白对照组和模型对照组给予等量蒸馏水灌胃,二甲双胍组灌胃二甲双胍,冠心消渴安胶囊对照组灌胃冠心消渴安胶囊。末次灌胃后禁食24h不禁水,麻醉大鼠后,腹主动脉取血分离血清。按照要求分别测定空腹血糖、空腹胰岛素、C反应蛋白、白介素-6含量根据大鼠空腹血糖、空腹胰岛素计算出胰岛素敏感指数、胰岛素抵抗指数。取大鼠冠脉及心肌组织备用。结果:1.成功建立糖尿病合并冠心病大鼠模型。2.二甲双胍对照组和冠心消渴安胶囊对照组与模型组对照组比较各项指标均优于模型对照组,且P0.05。在对大鼠模型空腹FINS,CRP,IL-6指标的影响上,冠心消渴安胶囊对照组明显优于二甲双胍对照组,P0.05。在对大鼠模型空腹FPG、IRI、ISI指标的影响上,二甲双胍对照组优于冠心消渴安胶囊对照组,P0.05。结论:1.在糖尿病合并冠心病大鼠模型上,冠心消渴安胶囊和二甲双胍降低FPG、IRI水平,提高了FINS、ISI水平。2.在糖尿病合并冠心病大鼠模型上,冠心消渴安胶囊和二甲双胍都降低CRP、IL-6水平,冠心消渴安胶囊效果优于二甲双胍。
[Abstract]:Diabetes mellitus complicated with coronary heart disease (CHD) is a kind of cardiovascular disease which is caused by various pathogenic factors on the basis of diabetes mellitus. In recent years, with the increasing incidence of diabetes mellitus and coronary heart disease in China, the incidence of diabetes with coronary heart disease has gradually increased, which seriously affected the health of the people. Chinese medicine has accumulated a lot of experience in the treatment of this disease. In order to reduce the economic burden of society, patients' families, reduce the variety of medication, ease the pain of medication. Guanxin Xiaoke an capsule is a Chinese patent medicine developed by Professor du Tinghai to treat diabetes and protect cardiovascular system. It is hoped that the pharmacodynamics and medicinal mechanism of Guanxin Xiaokean capsule can be confirmed by this animal experimental study. Objective: to establish a rat model of diabetes mellitus with coronary heart disease (CHD). The electrocardiogram (ECG) of rat model and the pathological sections of coronary artery and myocardial tissue were observed. To observe the effect of Guanxinxiaokean capsule on fasting blood glucose (Fasting plasma glucose FPG), fasting insulin (Fasting insulin FINS), insulin sensitivity index (Insulin sensitivity index ISI), insulin resistance index (Insulin resistance index IRI) and C-reactive protein (C-reactive protein CRP), white) in diabetic coronary heart disease rats The effect of interleukin-6 (Interleukin IL-6) level, To verify the curative effect of Guanxinxiaokean capsule on diabetic coronary heart disease, and to explore the mechanism of medicine, and to provide reliable experimental basis for clinical use of drugs. Methods: the diabetic rat model was established by intraperitoneal injection of streptozotocin (STZ) after feeding with high fat diet. After the establishment of diabetic rat model, the rat model of diabetes with coronary heart disease was established by intraperitoneal injection of pituitrin injection. The results of rat model were determined by observing the pathological sections of electrocardiogram, coronary artery and myocardial tissue. The model was divided into three groups: blank control group (group A), model control group (group B), metformin group (group C) and Guanxinxiaokean capsule group (group D). The rats in the control group were given the same amount of distilled water, the metformin group was given the same amount of metformin, and the control group was given the Guanxin Xiaokean capsule. The rats were anesthetized after 24 hours fasting. Blood samples were taken from the abdominal aorta to separate the serum. Fasting plasma glucose, fasting insulin C-reactive protein and interleukin-6 were measured according to the requirements. The insulin sensitivity index and insulin resistance index were calculated according to fasting blood glucose and fasting insulin in rats. Coronary artery and myocardial tissue were taken from rats. The result is 1: 1. Successful establishment of diabetes mellitus with coronary heart disease rat model. 2. 2. The indexes of metformin control group and Guanxinxiaokean capsule control group were better than that of model control group (P0.05). The effect of Guanxinxiaokean capsule on fasting FINS,CRP,IL-6 in rat model was significantly better than that of metformin control group (P0.05). The effect of metformin on the fasting FPG,IRI,ISI index of rat model was better than that of Guanxin Xiaokean capsule control group (P0.05). Conclusion 1. In diabetic rats with coronary heart disease, Guanxinxiaokean capsule and metformin decreased the level of FPG,IRI and increased the level of FINS,ISI. 2. Both Guanxinxiaokean capsule and metformin decreased CRP,IL-6 level in diabetic rats with coronary heart disease, and the effect of Guanxin Xiaokean capsule was better than metformin.
【学位授予单位】：河南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R285.5;R-332

【相似文献】